CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

ABSTRACT: Targeted T cell immunotherapies using engineered T lymphocytes expressing tumor-directed chimeric antigen receptors (CARs) are designed to benefit patients with cancer. Although incorporation of costimulatory endodomains within these CARs increases the proliferation of CAR-redirected T lymphocytes, it has proven difficult to draw definitive conclusions about the specific effects of costimulatory endodomains on the expansion, persistence, and antitumor effectiveness of CAR-redirected T cells in human subjects, owing to the lack of side-by-side comparisons with T cells bearing only a single signaling domain. We therefore designed a study that allowed us to directly measure the consequences of adding a costimulatory endodomain to CAR-redirected T cells. Patients with B cell lymphomas were sim

SUBMITTER: Savoldo B 

PROVIDER: S-EPMC3083795 | biostudies-literature | 2011 May

REPOSITORIES: biostudies-literature